MYCN protein stability is a better prognostic indicator in neuroblastoma

Objective MYCN oncogene amplification is associated with treatment failure and poor prognosis in neuroblastoma. To date, most detection methods of MYCN focus on DNA copy numbers instead of protein expression, which is the real one performing biological function, for poor antibodies. The current inve...

Full description

Saved in:
Bibliographic Details
Published in:BMC pediatrics 2022-07, Vol.22 (1), p.1-404, Article 404
Main Authors: Yang, Yi, Zhao, Jie, Zhang, Yingwen, Feng, Tianyue, Yv, Bo, Wang, Jing, Gao, Yijin, Yin, Minzhi, Tang, Jingyan, Li, Yanxin
Format: Article
Language:English
Subjects:
Antibodies
Datasets
FISH
Gene amplification
Genetic aspects
Genomes
Health aspects
IHC
Medical prognosis
Medical research
MYCN
Neuroblastoma
Patient outcomes
Pediatrics
Prognosis
Protein expression
Protein stability
Proteins
Survival analysis
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective MYCN oncogene amplification is associated with treatment failure and poor prognosis in neuroblastoma. To date, most detection methods of MYCN focus on DNA copy numbers instead of protein expression, which is the real one performing biological function, for poor antibodies. The current investigation was to explore a fast and reliable way to detect MYCN protein expression and evaluate its performance in predicting prognosis. Methods Several MYCN antibodies were used to detect MYCN protein expression by immunohistochemistry (IHC), and one was chosen for further study. We correlated the IHC results of MYCN from 53 patients with MYCN fluorescence in situ hybridization (FISH) and identified the sensitivity and specificity of IHC. The relationship between patient prognosis and MYCN protein expression was detected from this foundation. Results MYCN amplification status detected by FISH was most valuable for INSS stage 3 patients. In the cohort of 53 samples, IHC test demonstrated 80.0-85.7% concordance with FISH results. Further analyzing those cases with inconsistent results, we found that patients with MYCN amplification but low protein expression tumors always had a favorable prognosis. In contrast, if patients with MYCN non-amplified tumors were positive for MYCN protein, they had a poor prognosis. Conclusion MYCN protein level is better than MYCN amplification status in predicting the prognosis of neuroblastoma patients. Joint of FISH and IHC could confirm MYCN protein stability and achieve better prediction effect than the singular method. Keywords: Neuroblastoma, MYCN, IHC, FISH, Protein stability
ISSN:1471-2431
1471-2431
DOI:10.1186/s12887-022-03449-1